Tryptamine Microbiota-Deregulated Aminoacyl-tRNA Biosynthesis: A Conceptual Evolution of the Role of Microbiota Tryptamine in Human Diseases provides a detailed investigation into tryptamine, its underlying mechanisms, and metabolism across multiple diseases. The book explores key concepts of tryptamine, its biosynthetic pathways, and its influence in disease, specifically focusing on the Alzheimer's disease-associated gut bacterial sequence (ADAS). Various neurodegenerative conditions are covered alongside cancer, diabetes, infections, and chromosomal aberrations. Additionally, a chapter on gut tryptamine in domestic and agricultural animals is included. The book closes with case studies involving FDG-PET imaging in the context of tryptamine-treated mouse models and Alzheimer's disease patients.
This book elucidates the implications of the gut microbiota-mediated tryptamine metabolism for human health, sharing insights into disease etiology, mechanisms, testing, prevention, and treatment. It is an ideal reference for researchers across the biomedical sciences.
Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.
Table of Contents
1. Introduction2. Human gut microbial metabolite tryptamine inducing neurodegeneration causes chromosome and genome instability
3. Mutagenicity and genotoxicity of naturally occurring tryptamines and their principle metabolites
4. Abundant urinary tryptamine as indicator of UTI and nosocomial infections
5. Proteus mirabilis, diseases and tryptamine
6. Microbial tryptophan metabolites in cancer and leishmaniasis
7. The effect of human microbial metabolome on multisensory integration in aging and neurodegenerative diseases
8. Retinitis Pigmentosa (RP): RP-causative gene mutations, RP-related gene mutations, mosaicism and gut microbiome
9. The tRNA aminoacylation interference in diseases
10. Tryptamine interfere with Cytochrome P450
11. Discovery of ADAS and Caudoviricetes prophage markers in metagenomics of type 2 diabetes and associated medical conditions
12. Tryptamine, ADAS and microbiome in Parkinson’s disease
13. Gut microbial ADAS and tryptamine in domestic and agricultural animals
14. Tryptamine, stem cell/progenitor protein biosynthesis and aminoacyl-tRNA biosynthesis
15. Tryptamine metabolite indole-3-acetic acid (IAA) in neurodegenerative diseases and other conditions
16. FDG-PET: tryptamine-treated mouse model and Alzheimer’s disease patients. Conceptual evolution of microbiota tryptamine role in human diseases
17. Epilepsy, tryptamine-induced seizures, malfunction of ion channels, electrolyte abnormalities and antibiotic resistance
18. Conclusions
